• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Brodalumab may be effective for difficult-to-treat psoriasis

byShirin BajajandAdam Whittington
January 3, 2015
in Chronic Disease, Dermatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with brodalumab was shown to be safe and efficacious in patients with psoriatic arthritis or who previously failed treatment with biologic therapy. 

Evidence Rating Level: 2 (Good)

Study Rundown: Psoriasis is a chronic inflammatory skin disease that classically presents with itchy red lesions with a silvery scale. A difficult-to-treat subgroup of these patients, those with a history of psoriatic arthritis (PsA) or those who have failed biologic therapy, necessitate more treatment options. These authors performed a secondary analysis on the safety and efficacy of brodalumab, a novel therapy previously shown to improve psoriatic outcomes, in a difficult-to-treat cohort. When comparing patients with or without history of biologic use and patients with or without self-reported PsA, there were similar improvements in outcome and quality of life as compared to those treated with a placebo, indicating the utility of the therapy even for patients classically considered to have difficult-to-treat disease. While the randomized-controlled double-blind, placebo-controlled design is inherently strong, the study had notable limitations: (1) the differences between the subgroups were not compared statistically, (2) history of psoriatic arthritis was self-reported, and (3) information regarding reason for discontinuation of biologic therapy was not collected.

Click to read the study in JAAD

Relevant Reading: Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies

In-Depth [randomized controlled trial]: Four separate measures assessing quality of life and psoriasis severity were used to evaluate the two subsets of patients with moderate-severe difficult-to-treat plaque psoriasis [(1) those with or without PsA and (2) with or without history of biologic use]. Among the sub-groups, the mean duration of psoriasis ranged from 17.3 years to 24.3 years. Within all sub-groups, there were similar trends of 75%, 90%, and 100% improvement at 12 weeks when compared to baseline using the Psoriasis Area and Severity Index score (PASI) in those that received either 140 mg or 210 mg of medication as compared to those that received placebo with one exception. In the 140 mg group, the percentage of patients with 100% improvement was observed to be higher in patients with a history of PsA. Analyzing the sub-groups using the Dermatology Life Quality Index (DLQI), Psoriasis Symptom Inventory (PSI) and Physician Global Assessment Scales (PGA) demonstrated similar results. The amount of adverse events in patients who received brodalumab as compare to placebo was comparable amongst all subgroups.

More from this author: Tech-aided surveillance of patients at high risk for melanoma aids early diagnosis, Indoor tanning linked to high skin cancer risk in US and abroad, Free drug samples may alter prescription habits of dermatologists, Atopic dermatitis may be more persistent than previously understood

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: Brodalumabpsoriasis
Previous Post

No benefit of erlotinib in combined hepatocellular carcinoma treatment

Next Post

Similar outcomes after supracervical vs. total hysterectomy

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention
StudyGraphics

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

January 28, 2022
#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease
StudyGraphics

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

December 16, 2021
#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment
StudyGraphics

#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment

August 13, 2021
Next Post
Similar outcomes after supracervical vs. total hysterectomy

Similar outcomes after supracervical vs. total hysterectomy

Venous thromboembolism after vaginal delivery rising, preventative measures lacking

No benefit to antibiotics for term rupture of membranes

Small screen exposure associated with decreased sleep duration, quality

Small screen exposure associated with decreased sleep duration, quality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.